Answers are grounded in this paper and cite their sources.
The rapid emergence of antimicrobial resistance has intensified the need for alternative anti-infective strategies. Antimicrobial peptides (AMPs) offer diverse mechanisms of action, but their translation remains constrained by poor physiological stability, host toxicity, and manufacturing costs. This review examines AMP development within a design-build-test-learn (DBTL) framework that connects computational discovery, peptide production, experimental evaluation, and iterative optimization. Proteome mining and generative artificial intelligence expand the accessible sequence space, while solid-phase synthesis, engineered microbial hosts, and cell-free systems convert selected sequences into testable molecules. Chemical modification and formulation provide complementary routes to improve stability and delivery. Standardized screening and in vivo studies then establish the evidence needed to prioritize candidates and inform subsequent design and production decisions. Throughout this cycle, activity must be optimized together with toxicity, stability, manufacturability, and delivery rather than treated as the sole measure of success. This review discusses applications in medicine, agriculture, food preservation, and biotechnology, and identifies remaining limitations in data quality, assay comparability, scale-up, and translational support. The DBTL framework provides a basis for coordinating these activities, although its practical value depends on experimentally validated feedback and application-specific development criteria.
No takes yet. Share an insight, caveat, or question.
Yinbiao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: